Rocket Pharmaceuticals, Inc. experienced a decrease in net loss for the first quarter of 2025 compared to the same period in 2024, primarily due to a reduction in research and development expenses, despite an increase in general and administrative costs.

Rocket Pharmaceuticals reported a net loss of $60.3 million for Q4 2024, with total operating expenses of $62.7 million. The company's cash, cash equivalents, and investments stood at $372.3 million, providing an operational runway into Q3 2026.

Rocket Pharmaceuticals reported cash, cash equivalents and investments of $235.7 million as of September 30, 2024. Enrollment was completed in the RP-A501 program for Danon disease and in the low dose cohort of the RP-A601 program for PKP2-ACM. Mikael Dolsten was appointed to the Board of Directors.

Rocket Pharmaceuticals reported its Q2 2024 financial results, highlighting the advancement of its clinical pipeline, including RP-A501 and RP-A601 cardiac programs, and progress towards FDA approval for KRESLADI. The company's cash, cash equivalents, and investments totaled $278.8 million, expected to fund operations into 2026.

Rocket Pharmaceuticals reported a net loss of $62.1 million for Q1 2024, with cash, cash equivalents, and investments totaling $330.3 million, expected to fund operations into 2026. The company highlighted progress in its clinical programs, including the EMA's review of RP-L102 for Fanconi Anemia and preparations for the potential approval of KRESLADI for severe LAD-I.

Rocket Pharmaceuticals reported a net loss of $59.7 million for the fourth quarter of 2023. The company's cash, cash equivalents, and investments totaled $407.5 million as of December 31, 2023, expected to fund operations into 2026. Rocket is advancing its pipeline of gene therapies and preparing for the potential launch of KRESLADI™ for severe LAD-I.

Rocket Pharmaceuticals reported positive results across its clinical gene therapy programs and expanded its leadership in AAV cardiac gene therapy. The company's cash runway of approximately $400 million is expected to fund operations through 2024.

Rocket Pharmaceuticals reported a net loss of $57.8 million for the third quarter of 2022. The company highlighted positive updates from its Phase 1 clinical trial in Danon Disease and announced the acquisition of Renovacor to extend its leadership in AAV-based cardiac gene therapy. With cash, cash equivalents, and investments of $306.5 million and additional net proceeds of $108.2 million from a recent equity offering, the company expects its operational runway to extend into the second half of 2024.

Rocket Pharmaceuticals reported positive results across all four clinical programs and made progress toward manufacturing readiness. The company maintains a healthy operational cash runway into the first half of 2024.

Rocket Pharmaceuticals reported a net loss of $44.2 million for the fourth quarter of 2021. The company highlighted positive clinical data from ongoing trials for Danon Disease, Leukocyte Adhesion Deficiency-I (LAD-I), and Fanconi Anemia (FA). They anticipate in-house AAV cGMP manufacturing readiness in Q2 2022 and expect their cash resources to fund operations into the second half of 2023.

Rocket Pharmaceuticals reported a net loss of $50.1 million for the third quarter of 2021. The company's cash, cash equivalents, and investments totaled $421.5 million as of September 30, 2021, which is expected to fund operations into the second half of 2023.

Rocket Pharmaceuticals reported a net loss of $34.5 million for the second quarter of 2021. They have $426.8 million in cash, cash equivalents and investments as of June 30, 2021, which is expected to fund operations into the second half of 2023.

Rocket Pharmaceuticals reported a net loss of $40.2 million for the first quarter of 2021. The company's cash, cash equivalents, and investments totaled $466.4 million, expected to fund operations into the second half of 2023. Key pipeline developments include pausing the RP-A501 Danon Disease program for additional risk mitigation and advancing the fifth gene therapy program in Infantile Malignant Osteopetrosis into patient dosing.